SAB BIOTHERAPEUTICS INC (SABS) — insider trading
Health Care · NASDAQ
SAB BIOTHERAPEUTICS INC (SABS) has 11 reported SEC Form 4 insider transactions in our data (latest 2026-09-17).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | Kropotova Alexandra | Officer (CHIEF MEDICAL OFFICER) | Shares withheld for taxes / exercise cost | 473 | — | — | Form 4 |
| 2026-06-25 | Kropotova Alexandra | Officer (CHIEF MEDICAL OFFICER) | Shares withheld for taxes / exercise cost | 988 | — | — | Form 4 |
| 2026-03-24 | Kropotova Alexandra | Officer (CHIEF MEDICAL OFFICER) | Shares withheld for taxes / exercise cost | 988 | — | — | Form 4 |
| 2026-02-03 | To Lucy | Officer (See Remarks) | Grant / award / vesting (derivative) | 2,400,000 | — | $0 | Form 4 |
| 2026-02-03 | Kropotova Alexandra | Officer (CHIEF MEDICAL OFFICER) | Grant / award / vesting (derivative) | 2,400,000 | — | $0 | Form 4 |
| 2026-02-03 | Bausch Christoph Lawrence | Officer (CHIEF OPERATING OFFICER) | Grant / award / vesting (derivative) | 1,800,000 | — | $0 | Form 4 |
| 2026-02-03 | Reich Samuel J | Director, Officer (CEO) | Grant / award / vesting (derivative) | 4,800,000 | — | $0 | Form 4 |
| 2026-02-03 | Sullivan Eddie Joe | Director, Officer (PRESIDENT) | Grant / award / vesting (derivative) | 3,000,000 | — | $0 | Form 4 |
| 2026-01-05 | ZACCARDELLI DAVID | Director | Grant / award / vesting (derivative) | 240,000 | — | $0 | Form 4 |
| 2026-01-05 | Jain Rita | Director | Grant / award / vesting (derivative) | 240,000 | — | $0 | Form 4 |
| 2025-12-16 | SKYLER JAY S | Director | Grant / award / vesting (derivative) | 150,000 | — | $0 | Form 4 |
Ask the chat about SABS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: SAB BIOTHERAPEUTICS INC (SABS).
Last updated 2026-09-17 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.